Immunocore Holdings (IMCR) Cost of Revenue (2023 - 2026)

Immunocore Holdings has disclosed Cost of Revenue across 4 years of filings, most recently posting $434000.0 for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $434000.0, down 47.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 million (up 41.44% YoY), and the FY2025 annual result was $5.1 million, up 86.27% from the prior year.
• Cost of Revenue came in at $434000.0 for Q1 2026 at Immunocore Holdings, down from $2.7 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $2.7 million in Q4 2025 to a low of $200000.0 in Q4 2023.
• The 4-year median for Cost of Revenue is $434000.0 (2026), against an average of $714615.4.
• Across the five-year window, Cost of Revenue jumped 719.09% in 2025 and plunged 47.77% in 2026, its largest moves.
• Immunocore Holdings' Cost of Revenue stood at $200000.0 in 2023, then jumped by 65.0% to $330000.0 in 2024, then jumped by 719.09% to $2.7 million in 2025, then slumped by 83.94% to $434000.0 in 2026.
• The last three Cost of Revenue figures came in at $434000.0 (Q1 2026), $2.7 million (Q4 2025), and $513000.0 (Q3 2025), per Business Quant data.